{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:03:07Z","timestamp":1793347387265,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.amjmed.2017.12.039","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T12:04:54Z","timestamp":1517400294000},"page":"874-882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":266,"title":["Brain Tumors"],"prefix":"10.1016","volume":"131","author":[{"given":"J. Ricardo","family":"McFaline-Figueroa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.amjmed.2017.12.039_bib0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/now127","article-title":"Updates in the management of brain metastases","volume":"18","author":"Arvold","year":"2016","journal-title":"Neuro Oncol"},{"issue":"suppl 4","key":"10.1016\/j.amjmed.2017.12.039_bib0015","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"10.1016\/j.amjmed.2017.12.039_bib0025","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-017-2516-7","article-title":"Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study","volume":"134","author":"Kromer","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.amjmed.2017.12.039_bib0035","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"issue":"5","key":"10.1016\/j.amjmed.2017.12.039_bib0040","first-page":"465","article-title":"[Epidemiology of brain tumors (author's transl)]","volume":"34","author":"Takakura","year":"1982","journal-title":"No to Shinkei"},{"key":"10.1016\/j.amjmed.2017.12.039_bib0045","series-title":"Neurologic Complications of Cancer","author":"DeAngelis","year":"2009"},{"issue":"6","key":"10.1016\/j.amjmed.2017.12.039_bib0050","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.55.6.754","article-title":"Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Silberstein","year":"2000","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.amjmed.2017.12.039_bib0055","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1212\/01.wnl.0000285084.93652.43","article-title":"Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"69","author":"Krumholz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2017.12.039_bib0060","author":"National Comprehensive Cancer Network"},{"issue":"4","key":"10.1016\/j.amjmed.2017.12.039_bib0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.amjmed.2017.12.039_bib0070","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-014-2080-6","article-title":"High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"93","author":"Del Principe","year":"2014","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.amjmed.2017.12.039_bib0075","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s004150050459","article-title":"The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis","volume":"246","author":"Straathof","year":"1999","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.amjmed.2017.12.039_bib0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.amjmed.2017.12.039_bib0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2017.12.039_bib0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.410330605","article-title":"Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?","volume":"33","author":"Vecht","year":"1993","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","article-title":"The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group","volume":"6","author":"Borgelt","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.amjmed.2017.12.039_bib0100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.amjmed.2017.12.039_bib0105","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.amjmed.2017.12.039_bib0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0115","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.amjmed.2017.12.039_bib0120","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.amjmed.2017.12.039_bib0125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.amjmed.2017.12.039_bib0130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.amjmed.2017.12.039_bib0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-009-9934-0","article-title":"WHO grade II and III meningiomas: a study of prognostic factors","volume":"95","author":"Durand","year":"2009","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1227\/01.NEU.0000068730.76856.58","article-title":"The natural history of incidental meningiomas","volume":"53","author":"Nakamura","year":"2003","journal-title":"Neurosurgery"},{"issue":"24","key":"10.1016\/j.amjmed.2017.12.039_bib0145","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.29639","article-title":"Extent of resection and overall survival for patients with atypical and malignant meningioma","volume":"121","author":"Aizer","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.amjmed.2017.12.039_bib0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"issue":"6123","key":"10.1016\/j.amjmed.2017.12.039_bib0155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"2 Neuro\u2013oncology","key":"10.1016\/j.amjmed.2017.12.039_bib0160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1212\/01.CON.0000464173.58262.d9","article-title":"High-grade gliomas","volume":"21","author":"de Groot","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"25","key":"10.1016\/j.amjmed.2017.12.039_bib0165","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.amjmed.2017.12.039_bib0170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.amjmed.2017.12.039_bib0175","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.amjmed.2017.12.039_bib0180","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2017.12.039_bib0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.amjmed.2017.12.039_bib0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurg"},{"issue":"10","key":"10.1016\/j.amjmed.2017.12.039_bib0195","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2017.12.039_bib0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.amjmed.2017.12.039_bib0205","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.amjmed.2017.12.039_bib0210","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstrom","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.amjmed.2017.12.039_bib0215","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.amjmed.2017.12.039_bib0220","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2017.12.039_bib0225","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/neuonc\/nou304","article-title":"Medical management of brain tumors and the sequelae of treatment","volume":"17","author":"Schiff","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.amjmed.2017.12.039_bib0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","article-title":"Epilepsy and brain tumors","volume":"134","author":"Englot","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"10.1016\/j.amjmed.2017.12.039_bib0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-017-0777-3","article-title":"Brain tumor-related epilepsy: a current review of the etiologic basis and diagnostic and treatment approaches","volume":"17","author":"Politsky","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"10.1016\/j.amjmed.2017.12.039_bib0240","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318300317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318300317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:14:54Z","timestamp":1757582094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934318300317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0002934318300317"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.12.039","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain Tumors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}